Group 1 - The overall market sentiment among prominent private equity firms is optimistic for the second half of the year, contrasting with previous years' cautious outlooks [2] - The average daily trading volume in A-shares has increased to over 1.3 trillion yuan, significantly higher than the 1.2 trillion yuan in the second half of last year and 860 billion yuan in the first half of last year, indicating improved market activity and a positive profit effect [2] - Investment opportunities are expanding beyond new consumption and innovative pharmaceuticals to include technology and cyclical industries, with a focus on AI, domestic semiconductor equipment, and high-end manufacturing [2] Group 2 - The external environment remains challenging, but the Chinese capital market shows resilience, with both A-shares and Hong Kong stocks performing well amid geopolitical tensions and monetary policy uncertainties [3] - Economic demand is currently low, but there are structural highlights in various industries, and liquidity has improved following tariff impacts, leading to a "structural bull" market in A-shares and Hong Kong stocks [3] - The government is addressing negative impacts from excessive competition in certain industries, which may present future investment opportunities [3] Group 3 - The liquidity in both mainland China and Hong Kong markets is abundant, with a historical divergence in short-term interest rates between the Hong Kong dollar and the US dollar, suggesting limited downside risk for the market [4] - The market has seen a resurgence in IPO activity and record-high average daily trading volumes, indicating a wealth of opportunities, particularly in technology innovation and globally competitive industries [4] - There is a focus on identifying investment opportunities in leading companies that remain unaffected by short-term shocks, as the overall industry trends are still in their early stages [4]

Core Viewpoint - Dalian Bai'ao Chemical Co., Ltd. is successfully transforming its business towards semiconductor equipment, showcasing significant growth in its high-end lithography machine segment and a strong order backlog [1][2]. Company Overview - Bai'ao Chemical has over 20 years of experience in the industrial biocide industry, with an annual production capacity exceeding 40,000 tons, making it the largest producer of isothiazolinone-based industrial biocide raw materials in Asia [1]. - The company has established semiconductor equipment as a strategic development direction in early 2024, marking a significant shift from its traditional industrial biocide business [1]. Semiconductor Equipment Business - Bai'ao Chemical acquired 54.63% voting rights in Suzhou Xinhuilian Semiconductor Technology Co., Ltd. (Xinhuilian) through capital increase and voting rights entrustment, integrating it into the company's consolidated financial statements [1]. - Xinhuilian specializes in the R&D, production, and sales of semiconductor equipment, with six major business segments including photolithography equipment and wet cleaning equipment [2]. Financial Performance - In 2024, Xinhuilian achieved operating revenue of 543 million yuan, a year-on-year increase of 215.75%, and a net profit attributable to shareholders of 97 million yuan, up 370.82% year-on-year [2]. - The gross profit margin for Xinhuilian was 51.31%, an increase of 20.12 percentage points compared to the previous year, with the photolithography equipment segment boasting a gross margin of 71.56% [2]. Customer Contracts - As of the end of 2024, Xinhuilian's top five customers had a total contract amount of 1.369 billion yuan, with over 1 billion yuan in contracts yet to be recognized as revenue [2][3]. - One significant customer accounted for a contract amount of 492 million yuan, including two major contracts for photolithography equipment scheduled for delivery in 2025 [3]. Market Outlook - The semiconductor equipment market is expected to experience rapid growth due to the increasing demand for specialized equipment and the domestic semiconductor industry's advancements [1][3].

Group 1 - The company is a leading enterprise in the domestic cryogenic technology field, achieving a dual-driven development model of "equipment manufacturing + gas operation" [1] - The core products in the equipment manufacturing segment include natural gas liquefaction devices and large air separation units, with the plate-fin heat exchangers being a domestic leader and exported to 53 countries and regions [1] - The company has diversified its operations by investing in the sales of natural gas, industrial gases, and rare gases, enhancing its overall competitiveness [1] Group 2 - Rising oil prices have led to increased upstream investment, with the economic viability of energy and chemical industries improving, particularly in coal chemical and synthetic gas sectors [2] - Fixed asset investment in the domestic petroleum, coal, and other fuel processing industries increased by 18.8% year-on-year from January to May 2025 [2] - The company signed new orders worth approximately 1.8 billion yuan in 2024, representing a year-on-year growth of over 25%, with overseas orders also showing significant growth [2] Group 3 - The gas operation segment is expanding, with the company investing in industrial and rare gases, which are expected to become new revenue growth sources as projects reach production capacity [3] - A joint venture with Korea's Posco Holdings marks the company's first step in both equipment and operation overseas, providing valuable experience for future expansions [3] - The profit margin for industrial gas operations is relatively high, and as the business expands, the company's profitability is expected to improve [3] Group 4 - The company is projected to achieve revenues of 3.23 billion, 3.86 billion, and 4.72 billion yuan from 2025 to 2027, with year-on-year growth rates of 18.8%, 19.7%, and 22.2% respectively [4] - Net profit attributable to the parent company is expected to reach 400 million, 510 million, and 630 million yuan during the same period, with significant growth in 2025 [4] - The company is assigned a target price of 20.9 yuan based on a 20x PE ratio for 2025, indicating a potential upside of approximately 39% from the current stock price [4]

华创证券研究所 证 券 研 究 报 告 中泰股份（300435）深度研究报告 强推（首次） 深冷技术专家，设备出海+气体运营打开成长 空间 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 2,717 | 3,228 | 3,863 | 4,720 | | 同比增速(%) | -10.9% | 18.8% | 19.7% | 22.2% | | 归母净利润(百万) | -78 | 403 | 506 | 628 | | 同比增速(%) | -122.3% | 616.3% | 25.8% | 24.0% | | 每股盈利(元) | -0.20 | 1.04 | 1.31 | 1.63 | | 市盈率(倍) | -74 | 14 | 11 | 9 | | 市净率(倍) | 1.9 | 1.8 | 1.4 | 1.1 | 资料来源：公司公告，华创证券预测 注：股价为 2025 年 7 月 4 日收盘价 公司研究 专用设备 2025 年 07 ...

Core Viewpoint - The company, Shanwaishan, is experiencing growth in its blood purification equipment sales and is well-positioned in the expanding domestic blood dialysis market due to increasing ESRD patient numbers and supportive government policies [2][3][5]. Industry Overview - The number of ESRD patients in China increased from 3.025 million in 2019 to 4.126 million in 2023, with a compound growth rate (CGR) of 8.1%, which is significantly higher than the global growth rate of 5.1% [2]. - The percentage of ESRD patients receiving dialysis treatment in China is approximately 26%, which is below the global average of 37% and significantly lower than the average of 75% in developed countries, indicating substantial market potential for blood dialysis services [2]. Company Performance - In Q1 2025, Shanwaishan's blood purification equipment achieved revenue of 127.49 million yuan, with strong growth in both domestic and international markets [3]. - The company's blood purification consumables generated revenue of 43.26 million yuan in Q1 2025, with a year-on-year growth of 123.46% [5][6]. - The medical services segment reported revenue of 16.27 million yuan in Q1 2025, reflecting a year-on-year increase of 43.52% [6]. Competitive Advantages - Shanwaishan maintains a strong competitive edge through technological innovation, product quality, brand influence, and rapid service response [4]. - The company has established a national-level technology innovation platform and a comprehensive quality management system, ensuring product safety and reliability [4]. - As the only Sci-Tech Innovation Board listed company in the blood purification industry, Shanwaishan's brand recognition is increasing, enhancing market trust and acceptance [4]. Market Trends and Policies - The Chinese government is promoting policies to enhance the efficiency of medical equipment funding and reduce financing costs for equipment updates, which is expected to increase demand for blood dialysis equipment in hospitals [5][6]. - The company is actively monitoring and participating in the implementation of relevant procurement policies to capitalize on market opportunities [6].

Core Viewpoint - The company, Dalian Baiao Chemical Co., Ltd., reported a revenue of 1.312 billion yuan for its industrial biocide business in 2024, reflecting a year-on-year growth of 23.09%. However, the gross profit margin decreased by 8.28 percentage points to 44.30% due to increased competition and pricing pressures in the market [2][5]. Group 1: Financial Performance - The industrial biocide business generated 1.207 billion yuan in revenue, accounting for 92% of the main business income, with over 60% of this revenue coming from overseas markets [2][3]. - The company’s overseas revenue from 2021 to 2024 showed an upward trend, increasing from 471 million yuan in 2021 to 762 million yuan in 2024 [2]. - The average selling price of industrial biocide products decreased by 14.95%, while the unit cost increased by 0.70%, leading to an overall decline in gross profit margin [5][6]. Group 2: Product and Market Analysis - The company specializes in the research, production, and sales of isothiazolinone-based industrial biocides, with no direct competitors listed in the public market [5][6]. - The average sales prices of key products, such as CMIT/DCOIT and BIT series, experienced significant declines, with CMIT/DCOIT prices dropping by 25.03% [5][6]. - The company faced increased competition as domestic manufacturers expanded production capacity, leading to downward pressure on product prices [5][6]. Group 3: Customer and Supply Chain Insights - The company provided details on its top ten overseas customers, including their sales amounts and operational details, confirming that there are no related party transactions with these customers [8][9]. - The logistics and transportation costs for overseas sales have fluctuated significantly, with transportation expenses rising by 129.37% in 2024 compared to the previous year [10][11]. - The company’s overseas business transportation costs were primarily borne by the company, with major carriers being large international shipping companies [10][11]. Group 4: Semiconductor Business Overview - In 2024, the company acquired a 54.63% stake in Chipwise, which achieved a net profit of 103.29% of its performance commitment, indicating strong operational performance [13][14]. - Chipwise's revenue for 2024 reached 543.46 million yuan, with a significant increase in gross profit margin due to successful product lines [16][18]. - The company’s cash flow from operating activities for Chipwise remained negative, primarily due to high procurement costs for semiconductor equipment [17][18].

Group 1 - In June, 1,100 private securities products were registered, a month-on-month increase of 26.44%, with a total of 5,461 products registered in the first half of the year, representing a year-on-year increase of 53.61% [1] - Stock strategy products accounted for over 60% of the registered private securities products in the first half of the year, with 3,458 products [1] - The majority of private fund managers were subjective private funds, totaling 1,007, which is 56.73% of the total [1] Group 2 - In June, 751 private fund managers conducted research on 387 A-share companies, totaling 1,769 times, with the electronics and biopharmaceutical industries being the most favored [2] - 46 stocks received significant attention from private institutions, with Maiwei Biotech being the most favored, receiving 51 research visits [2] Group 3 - The top five private funds in terms of research frequency in June were Zhengyuan Fund, Pankin Investment, Shangcheng Asset, Danshuiquan, and Qingli Investment, with 39, 23, 22, 22, and 21 visits respectively [3] - Zhengyuan Fund focused on Shunwang Technology, Xinjie Electric, and Lingyun Light, while Pankin Investment concentrated on Maiwei Biotech, Xianheng International, and Shunwang Technology [3] Group 4 - Many star private equity firms remain optimistic about the market outlook, although some express concerns about the sustainability of the current market state [4] Group 5 - Dushuquan believes that the second half of the year will see new emerging growth assets become the focus, driven by a shift from risk aversion to opportunity in the market [5] - The firm highlights the resilience of the market despite external pressures, with a daily trading volume exceeding 1.3 trillion yuan [5] Group 6 - Wellington's survey indicates that 96% of LPs plan to increase or maintain their allocation to the private equity market, with 51% believing that mixed strategies can enhance portfolio performance [10] - The survey shows a trend towards diversification in asset allocation among LPs, with a focus on private equity secondary markets and growth assets [10] Group 7 - Five insurance-funded private equity firms have been approved, with a total of 2,220 billion yuan allocated for long-term investment in the stock market [11][17] - The approval of these firms indicates a growing trend of insurance capital entering the private equity market for long-term investments [11][17]

证券研究报告 | 策略点评 2025 年 07 月 04 日 投资要点 分析师：孟之绪 执业编号：S0300524080001 电话： 邮箱：mengzhixu@ykzq.com 投资策略研究 股市有风险，投资需谨慎。 请务必阅读最后特别声明与免责条款 www.ykzq.com 1 / 6 粤开市场日报-20250704 今日关注 指数涨跌情况：今日 A 股主要指数多数收跌。截止收盘，沪指涨 0.32%，收报 3472.32 点；深证成指跌 0.25%，收报 10508.76 点；科创 50 跌 0.01%，收报 984.80 点；创业板指跌 0.36%，收报 2156.32 点。总体上，全天个股跌多涨 少，Wind 数据显示，全市场 4118 只个股下跌，1169 只个股上涨，129 只个股 收平。沪深两市今日成交额合计 14285 亿元，较上个交易日放量 1188.11 亿 元。 行业涨跌情况：今日申万一级行业涨少跌多，银行、传媒、综合、公用事业、 钢铁、煤炭等行业领涨，美容护理、有色金属、基础化工、轻工制造、环保、 机械设备等行业领跌。 板块涨跌情况：今日涨幅居前概念板块为跨境支付、央企银行、数字货币、 ...

Core Viewpoint - The company reported a decline in revenue and profit for 2024, but showed signs of recovery in Q1 2025, with a focus on both domestic and international market expansion [1][2][3]. Financial Performance - In 2024, the company achieved revenue of 10.3 billion yuan, a decrease of 9.73%, and a net profit of 1.262 billion yuan, down 36.1% [1]. - Q4 2024 revenue was 3.35 billion yuan, down 15.91%, with a net profit of 591 million yuan, down 35.1% [1]. - In Q1 2025, revenue increased to 2.478 billion yuan, up 5.42%, with a net profit of 370 million yuan, up 1.87% [1]. Business Segments - Domestic sales of medical imaging and radiation therapy equipment generated 8.445 billion yuan, a decline of 14.93%, while the service segment grew by 26.81% to 1.356 billion yuan [2]. - International revenue reached 2.266 billion yuan, an increase of 35.08%, accounting for 22% of total revenue, driven by market penetration in high-end segments [2]. R&D and Innovation - The company invested 2.261 billion yuan in R&D in 2024, representing 21.95% of revenue, and 568 million yuan in Q1 2025, accounting for 22.92% of revenue [3]. - The company has achieved significant advancements in technology across various product lines, establishing a competitive edge in the market [3]. Market Strategy - The company is focusing on a dual strategy of high-end product development and comprehensive market penetration domestically, while enhancing localized operations internationally [3]. - The global service network now covers over 85 countries and regions, supporting the operational needs of more than 34,500 devices [3].

导读： 项目分为26包进行采购，总预算达1.15亿元，涉及质谱、电子显微镜、X射线衍射仪、核磁共振波谱仪、细胞成像分析系统等26台/套仪器设备，部分采购 需求中明确要求不允许采购进口产品。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 7月2日，中国科学院2025年仪器设备部门批量集中采购项目发布招标公告。 该项目分为26包进行采购，总预算达 1.15亿元 ，涉及 质谱、电子显微镜、X射线衍射仪、核磁共振波谱仪、细胞成像分析系统 等 26台/套 仪 器设备。 其中第1包、第13包、第20包、第24包 采购需求中明确表明， 纳米晶体电子衍射仪、三重四极杆电感耦合等离子无机质谱、激光共聚焦扫描 显微镜、超高效液相色谱-串联四极杆质谱联用系统 不允许采购进口产品 。 采购代理机构为东方国际招标有限责任公司，要求潜在投标人应在www.oitccas .com；北京市海淀区丹棱街1号互联网金融中心20层获取招 标文件，并于 2025年07月23日14点00分 （北京时间） 前递交投标文件。 为方便业内人士查询，仪器信息网特对相关招标信息进行梳理并制 ...